ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2012-05-14
What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-05-14 (fiscal Q3 2012): 26 published measures, 75 facts as tagged in accession 0001144204-12-028430.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2012-05-14
- Fiscal period
- fiscal Q3 2012
- Accession
- 0001144204-12-028430 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 8,634,583 | USD | |
| At 2011-06-30 | 8,596,889 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 4,035,577 | USD | |
| At 2011-06-30 | 4,079,426 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 4,599,006 | USD | |
| At 2011-06-30 | 4,517,463 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 3,207,251 | USD | |
| At 2011-06-30 | 3,609,954 | USD | |
| At 2011-03-31 | 4,860,893 | USD | |
| At 2010-06-30 | 8,026,296 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -1,060,659 | USD | 91 |
| 2011-07-01 to 2012-03-31 | -3,627,213 | USD | 275 |
| 1998-07-01 to 2012-03-31 | -55,497,834 | USD | 5023 |
| 2011-01-01 to 2011-03-31 | -1,405,108 | USD | 90 |
| 2010-07-01 to 2011-03-31 | -4,557,147 | USD | 274 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | -3,277,907 | USD | 275 |
| 1998-07-01 to 2012-03-31 | -35,914,248 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | -4,367,896 | USD | 274 |
Capital expenditure payments
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 4,461 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 184,666 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | 2,026 | USD | 274 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 200,000 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 1,790,000 | USD | 5023 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 3,218,879 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 45,424,056 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | 1,639,460 | USD | 274 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | -343,675 | USD | 275 |
| 1998-07-01 to 2012-03-31 | -6,302,557 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | -436,967 | USD | 274 |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 6,454 | USD | |
| At 2011-06-30 | 3,782 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 609,875 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 11,949,824 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | 568,025 | USD | 274 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -1,108,729 | USD | 91 |
| 2011-07-01 to 2012-03-31 | -3,845,012 | USD | 275 |
| 1998-07-01 to 2012-03-31 | -49,814,903 | USD | 5023 |
| 2011-01-01 to 2011-03-31 | -1,367,801 | USD | 90 |
| 2010-07-01 to 2011-03-31 | -5,078,229 | USD | 274 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 4,942,723 | USD | |
| At 2011-06-30 | 5,056,018 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 3,532,949 | USD | |
| At 2011-06-30 | 3,268,439 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 804,781 | USD | |
| At 2011-06-30 | 559,525 | USD |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 540,789 | USD | 91 |
| 2011-07-01 to 2012-03-31 | 1,926,492 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 20,595,850 | USD | 5023 |
| 2011-01-01 to 2011-03-31 | 800,341 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 3,135,200 | USD | 274 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 91,872,182 | shares | |
| At 2011-06-30 | 77,769,677 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 69,511,823 | USD | |
| At 2011-06-30 | 64,488,152 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 3,680,235 | USD | |
| At 2011-06-30 | 3,524,731 | USD |
Other noncurrent liabilities
Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 99,728 | USD | |
| At 2011-06-30 | 99,728 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2012-03-31 | 529,060 | USD | |
| At 2011-06-30 | 509,806 | USD |
Net income available to common stockholders
Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | -1,480,139 | USD | 91 |
| 2011-07-01 to 2012-03-31 | -5,083,153 | USD | 275 |
| 1998-07-01 to 2012-03-31 | -65,831,588 | USD | 5023 |
| 2011-01-01 to 2011-03-31 | -2,121,888 | USD | 90 |
| 2010-07-01 to 2011-03-31 | -6,955,941 | USD | 274 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2012-01-01 to 2012-03-31 | 567,940 | USD | 91 |
| 2011-07-01 to 2012-03-31 | 2,118,520 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 31,009,053 | USD | 5023 |
| 2011-01-01 to 2011-03-31 | 567,460 | USD | 90 |
| 2010-07-01 to 2011-03-31 | 1,943,029 | USD | 274 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 1998-07-01 to 2012-03-31 | 205,390 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | -115,869 | USD | 274 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2011-07-01 to 2012-03-31 | 245,256 | USD | 275 |
| 1998-07-01 to 2012-03-31 | 804,781 | USD | 5023 |
| 2010-07-01 to 2011-03-31 | -47,139 | USD | 274 |
Inspect the source
- Entity
- ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
- Captured
- 2026-09-20T05:15:09.498Z
- SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))